ACHN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACHN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. Achillion Pharmaceuticals's Net Income for the three months ended in Sep. 2019 was $-19.58 Mil. Achillion Pharmaceuticals's Revenue for the three months ended in Sep. 2019 was $0.00 Mil. Therefore, Achillion Pharmaceuticals's net margin for the quarter that ended in Sep. 2019 was 0.00%.
The historical rank and industry rank for Achillion Pharmaceuticals's Net Margin % or its related term are showing as below:
The historical data trend for Achillion Pharmaceuticals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Achillion Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||||
Net Margin % | Get a 7-Day Free Trial | - | -7.61 | -411.37 | - | - |
Achillion Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | |
Net Margin % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Achillion Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Achillion Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Achillion Pharmaceuticals's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Achillion Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2018 is calculated as
Net Margin | = | Net Income (A: Dec. 2018 ) | / | Revenue (A: Dec. 2018 ) |
= | -70.272 | / | 0 | |
= | % |
Achillion Pharmaceuticals's Net Margin for the quarter that ended in Sep. 2019 is calculated as
Net Margin | = | Net Income (Q: Sep. 2019 ) | / | Revenue (Q: Sep. 2019 ) |
= | -19.583 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Achillion Pharmaceuticals (NAS:ACHN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Achillion Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Joseph Truitt | director, officer: Chief Executive Officer | C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
Kurt Graves | director | C/O ACHILLION PHARMACEUTICALS INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
Michael D Kishbauch | director | 18 CHERRYVILLE RD, FLEMINGTON NJ 08822 |
Jason S Fisherman | director | C/O ADVENT INTERNATIONAL CORP, 75 STATE ST 29TH FLOOR, BOSTON MA 02104 |
Van Nostrand Robert L | director | C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
Nicole Vitullo | director | 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
Martha E Manning | officer: General Counsel | 700 PENNSYLVANIA DR, EXTON PA 19341 |
Frank Verwiel | director | C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005 |
Paul E Firuta | officer: EVP, Chief Commercial Officer | 550 HILLS DRIVE, THIRD FLOOR, BEDMINSTER NJ 07921 |
Steven Zelenkofske | officer: EVP, Chief Medical Officer | 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920 |
Mary Kay Fenton | officer: Chief Financial Officer | ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511 |
Milind Deshpande | director, officer: Chief Executive Officer | ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511 |
Johnson & Johnson Innovation - Jjdc, Inc. | 10 percent owner | 410 GEORGE STREET, NEW BRUNSWICK NJ 08901 |
Johnson & Johnson | 10 percent owner | ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933 |
David Apelian | officer: Chief Medical Officer | C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511 |
From GuruFocus
By Marketwired Marketwired • 03-08-2019
By Marketwired Marketwired • 12-19-2019
By Marketwired Marketwired • 08-08-2019
By Marketwired Marketwired • 10-24-2019
By Marketwired Marketwired • 05-14-2019
By Marketwired Marketwired • 02-21-2019
By [email protected] insider • 10-18-2019
By PRNewswire PRNewswire • 10-16-2019
By Marketwired Marketwired • 06-10-2019
By Marketwired Marketwired • 07-22-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.